Clinical Trials Directory

Trials / Completed

CompletedNCT01340937

A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)

A Phase III Randomized, Partially Double-Blind, Active-Comparator-Controlled, Lot-to-Lot Consistency Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 6 Months Concomitantly With Prevnar 13™ and RotaTeq ™

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
2,808 (actual)
Sponsor
Merck Sharp & Dohme LLC · Industry
Sex
All
Age
46 Days – 89 Days
Healthy volunteers
Accepted

Summary

This study will determine whether three manufacturing lots of V419 (PR5I) induce similar immune responses to all of the antigens contained in V419 when given concomitantly with Prevnar13™ and RotaTeq™.

Detailed description

This study is partially Double-Blinded in that the participants' parents/guardians, investigator/study site personnel, and Sponsor's representatives will be blinded to the lot of V419 the participant is randomized to receive, but not to the participant's treatment group (V419 or control).

Conditions

Interventions

TypeNameDescription
BIOLOGICALV419V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate \[Meningococcal Outer Membrane Protein Complex\], and Hepatitis B \[Recombinant\] Vaccine) (from one of three lots) 0.5 mL intramuscular injection at 2, 4, and 6 months of age.
BIOLOGICALPENTACEL™PENTACEL™ 0.5 mL intramuscular injection at 15 months of age in the V419 groups and at 2, 4, 6, and 15 months of age in the control group
BIOLOGICALPrevnar 13™Prevnar 13™ 0.5 mL intramuscular injection at 2, 4, 6, and 15 months of age
BIOLOGICALRotaTeq™RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
BIOLOGICALRecombivax HB vaccineRecombivax HB vaccine 0.5 mL intramuscular injection at 2 and 6 months of age

Timeline

Start date
2011-05-10
Primary completion
2012-12-18
Completion
2013-07-26
First posted
2011-04-25
Last updated
2018-11-15
Results posted
2016-05-02

Source: ClinicalTrials.gov record NCT01340937. Inclusion in this directory is not an endorsement.